BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin.
5mg once daily. Reevaluate at 6 months, then periodically.
Type II 5 alpha-reductase inhibitor.
Not for use in children or women. Pregnant women and those of childbearing potential should avoid handling crushed or broken tablets.
Not for use in preventing prostate cancer. Increased risk of high-grade prostate cancer. Monitor prostate specific antigen (PSA) values; double PSA levels for comparison with normal ranges. Rule out prostate cancer and other urological disorders prior to treatment. Monitor for obstructive uropathy. Hepatic dysfunction.
Impotence, decreased libido or ejaculate volume, mastodynia.
Tabs—30, 100, 1000